TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2185298
Drug: Ascites recirculation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascites recirculation and daily paracentesis
Study: 7387803
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (10 ml of a 10% solution, containing elemental calcium 27 mg ml‐1)
Study: 7387803
Drug: Calcium gluceptate
Normalized name: Calcium Gluceptate
DrugBank: Calcium glucoheptonate (DB00326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluceptate (20 ml, containing elemental calcium 18 mg ml‐1)
Study: 30834520
Drug: Concurrent exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exposure to maternal socioeconomic and psychosocial indicators of adversity
Study: 30479999
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) delivered by respiratory nurses
Study: 11463510
Drug: Levetiracetam (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (2000 mg/day)
Study: 9711471
Drug: Bromazepam 1.5
Normalized name: bromazepam 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 1.5 mg
Study: 30734359
Drug: Case vignettes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Case vignettes for oral healthcare management
Study: 23926585
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B P40®)
Study: 18541517
Drug: Hypoxia-targeted therapeutics
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia-targeted therapeutics (e.g., tirapazamine, AQ4N)
Study: 18541517
Drug: Standard chemotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapeutic agents
Study: 17162245
Drug: UDCA 12-15
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 12-15 mg.kg-1.day-1 with vitamin E 400 IU twice a day (UDCA/Vit E)
Study: 8725891
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) before radical prostatectomy
Study: 26958746
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure-lowering therapy (target systolic blood pressure, < 140 mm Hg within 1 hr)
Study: 26958746
Drug: Guideline-recommended blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended blood pressure-lowering therapy (target systolic blood pressure, < 180 mm Hg)
Study: 24931951
Drug: 3-drug therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-drug therapy
Study: 24931951
Drug: monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monotherapy
Study: 9521221
Drug: Atorvastatin (Lipitor)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (Lipitor) at dosages of 10 to 80 mg/d
Study: 7986114
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy of CDDP+VDS
Study: 7986114
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + postoperative chemotherapy with CDDP+5‐FU
Study: 2736615
Drug: Subcutaneous group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous group (I)
Study: 2736615
Drug: Intradermal group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal group (II)
Study: 4923653
Drug: L-dopa (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (10 weeks treatment)
Study: 29208255
Drug: Ice cream
Normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cream test
Study: 18575277
Drug: 75-g OGTT
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-g OGTT
Study: 29208255
Drug: Ice cream
Normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cream test and 75-g OGTT
Study: 21223551
Drug: Aspirin (trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (trial medication)
Study: 12729348
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of BCG vaccination
Study: 12729348
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of BCG vaccination
Study: 9296529
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 3 IU/m2 per day for group 1 (n=6)
Study: 9296529
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 4.5 IU/m2 per day for group 2 (n=6)
Study: 9296529
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 3 IU/m2 per day in the 1st year and 4.5 IU/m2 per day thereafter for group 3 (n=5)
Study: 9296529
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 4 years (14 children) and 5 years (8 children)
Study: 8326054
Drug: Behavioral couple
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couple therapy
Study: 8326054
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behavioral couple therapy and cognitive-behavioral therapy
Study: 19995097
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (9.5 mg/24 h)
Study: 20937977
Drug: Lasofoxifene 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.5 mg/d
Study: 20937977
Drug: Lasofoxifene 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.25 mg/d
Study: 16253807
Drug: Endurance-trained subjects;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance-trained subjects; Distribution volume of [11C]TMSX in myocardium: 3.6+/‐0.3 ml g(‐1); Triceps brachii muscle: 1.7+/‐0.3 ml g(‐1)
Study: 16253807
Drug: Untrained subjects;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untrained subjects; Distribution volume of [11C]TMSX in myocardium: 3.1+/‐0.4 ml g(‐1); Triceps brachii muscle: 1.2+/‐0.2 ml g(‐1)
Study: 1694294
Drug: Aspartame (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (34 mg/kg)
Study: 1694294
Drug: Sucrose (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (1.75 g/kg)
Study: 1694294
Drug: Aspartame (9.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (9.7 mg/kg)
Study: 31924158
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice with cyclosporine (100 mg cyclosporine + 500 ml pomegranate juice)
Study: 31924158
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with cyclosporine (100 mg cyclosporine + 500 ml water)
Study: 29619799
Drug: Low-carbohydrate, ketogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate, ketogenic diet (LC; <50 g/day and <10% of energy from carbohydrates)
Study: 29619799
Drug: High-carbohydrate diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate diet (HC; 6-10 g/kg/day carbohydrate)
Study: 24001080
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) midazolam
Study: 24001080
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) lorazepam
Study: 18302621
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction/chlorhexidine + cetyl pyridinium gargling
Study: 16569890
Drug: Ritonavir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (100 mg BID) with fosamprenavir (700 mg BID)
Study: 16569890
Drug: Ritonavir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (100 mg BID) with amprenavir (600 mg BID)
Study: 16569890
Drug: Fosamprenavir (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir (700 mg BID) alone
Study: 16569890
Drug: Amprenavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir (600 mg BID) alone
Study: 11185675
Drug: Digoxin 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.375 mg plus 8 mg rosiglitazone
Study: 11185675
Drug: Digoxin 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.375 mg plus matching placebo
Study: 1316077
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once daily for 10-14 days
Study: 1316077
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg every 12 hours for 10-14 days
Study: 22154198
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment for 6 months, titrated to 40 mg/d
Study: 18083750
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no atorvastatin treatment)
Study: 9052303
Drug: Infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion group (Group I, n = 6)
Study: 9052303
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection group (Group II, n = 9)
Study: 3512534
Drug: Imipramine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine up to 200 mg/day (mean = 130 mg/day)
Study: 3512534
Drug: 12 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weekly therapist‐assisted in vivo exposure sessions (flooding)
Study: 29704557
Drug: Mabfilin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mabfilin and Fabfilin molecules
Study: 16282697
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day from 2 days after surgery
Study: 14662211
Drug: Corticosteroids (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (intravenous methylprednisolone 125 mg followed by oral prednisone taper: 40 mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days)
Study: 3519097
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg fipexide daily
Study: 27449221
Drug: Kunxian capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kunxian capsules (0.6 g, three times per day) for 12 weeks
Study: 27449221
Drug: Kunxian capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kunxian capsules
Study: 18427362
Drug: Conventional quadrant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional quadrant therapy
Study: 16167471
Drug: Synbiotic 2000
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic 2000 (four different lactobacilli preparations with 10^10 CFU and prebiotics)
Study: 12598350
Drug: Alternating regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating regimen (docetaxel 100 mg/m2, doxorubicin 75 mg/m2, cycle-by-cycle alternating)
Study: 12598350
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen (docetaxel 100 mg/m2, doxorubicin 75 mg/m2, sequential for four cycles)
Study: 10492276
Drug: 99mTc DTPA
Normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 99mTc DTPA aerosol inhalation lung scintigraphy
Study: 7369913
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefaclor
Study: 6357076
Drug: Carboxypenicillin-aminoglycoside combination
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carboxypenicillin-aminoglycoside combination
Study: 31215755
Drug: Verubecestat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (100 mg single dose or 30, 80, and 120 mg multiple doses once daily for 28 days)
Study: 18780164
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release formulation with immediate release element
Study: 18780164
Drug: Four formulations
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four formulations of Galantamine
Study: 10695942
Drug: Metronidazole 250
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 250 mg plus Amoxicillin 500 mg (M+A)
Study: 29695370
Drug: Hinge Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hinge Health digital care program for chronic knee pain (12-week intervention including sensor-guided exercise therapy, education, cognitive behavioral therapy, weight loss, and psychosocial support)
Study: 22052584
Drug: Febuxostat 240
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 240 mg
Study: 18975369
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 or 100 mg)
Study: 18975369
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg (impaired renal function)
Study: 18975369
Drug: Febuxostat 120
Normalized name: Febuxostat 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 120 mg (impaired renal function)
Study: 18975369
Drug: Febuxostat 240
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 240 mg (impaired renal function)
Study: 18975369
Drug: Allopurinol 100
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100 mg (impaired renal function)
Study: 16472565
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 500 mg twice a day for 5 days
Study: 28840615
Drug: Curcumin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1 g/day)
Study: 17953475
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil/HCTZ (40/12.5 mg/day for 4 weeks; then 40/25 mg/day for 4 weeks)
Study: 17953475
Drug: Benazepril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril plus amlodipine besylate (20/5 mg/day for 4 weeks; then 20/10 mg/day for 4 weeks)
Study: 11209625
Drug: Combination prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination prostaglandin E2 (PGE2) gel and Foley catheter
Study: 9573676
Drug: Delayed intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed intensification therapy
Study: 9573676
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without delayed intensification therapy
Study: 18215600
Drug: Higher-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose statin therapy
Study: 18215600
Drug: Standard-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose statin therapy
Study: 12541393
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of doktarin ps cream (DC)
Study: 12541393
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ketoconazole cream (KEC)
Study: 12541393
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of clotrimazole ung (CU)
Study: 12541393
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of thymol alcohol (TA)
Study: 12541393
Drug: Systematic intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic intermittent impulsive treatment
Study: 12541393
Drug: Compound azoles
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound azoles drugs
Study: 9057377
Drug: Ampicillin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (100 mg/kg/day)
Study: 9057377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benzyl penicillin (100,000 units/kg/day) and chloramphenicol (100 mg/kg/day)
Study: 6684446
Drug: Thymostimulin (TP‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP‐1 Serono) in combination with antibiotic therapy
Study: 24342685
Drug: Monensin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monensin (18 g of monensin/t of dry matter)
Study: 22340476
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave treatment (ESWT), 20,000 shock wave impulses in 10 sessions over a two-week period
Study: 15758533
Drug: Clofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (100 mg/kg) plus phototherapy
Study: 10070909
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 400 mg daily for 6 months
Study: 1963125
Drug: High-soluble-fibre diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-soluble-fibre diet (5 g guar gum thrice daily)
Study: 1963125
Drug: High-glucose diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose diet (500 ml glucose drink providing 100 g glucose per day)
Study: 31174239
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan, with early radiation therapy (RT) at week 4 concurrent with irinotecan in the experimental arm.
Study: 26553448
Drug: HDM SLIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM SLIT tablet 6 SQ HDM
Study: 26553448
Drug: HDM SLIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM SLIT tablet 12 SQ HDM
Study: 17513690
Drug: Weekly automated
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly automated telephone disease management (ATDM)
Study: 17513690
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group medical visits
Study: 16243128
Drug: Fluconazole 6
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 6 mg/kg per day for 3 weeks followed by 3 weeks of placebo
Study: 16243128
Drug: Fluconazole 6
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 6 mg/kg per day for 6 weeks
Study: 16243128
Drug: Griseofulvin 11
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin 11 mg/kg per day for 6 weeks
Study: 14598620
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine and i.v. clonidine 1 microgram.kg‐1 (CLO group)
Study: 10766467
Drug: C+E (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (5 mg x kg(‐1) caffeine and 1 mg x kg(‐1) ephedrine)
Study: 10766467
Drug: C+E (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (4 mg x kg(‐1) caffeine and 1 mg x kg(‐1) ephedrine)
Study: 10766467
Drug: C+E (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (4 mg x kg(‐1) caffeine and 0.8 mg x kg(‐1) ephedrine)
Study: 10766467
Drug: C+E (lowest
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (lowest dose: 4 mg x kg(‐1) caffeine and 0.8 mg x kg(‐1) ephedrine)
Study: 10766467
Drug: C+E (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (all doses)
Study: 1481117
Drug: Continuous hyperfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperfractionated accelerated radiotherapy combined with chemotherapy (20 mg mitomycin C/m2 on day 5)
Study: 29381191
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (InO) at a starting dose of 1.8 mg/m2/cycle (0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15 of a 21- to 28-day cycle, ≤6 cycles)
Study: 22578498
Drug: Levetiracetam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (low dose)
Study: 17653020
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg IV over 30 min, then 20 mg/kg/24 h if needed)
Study: 17653020
Drug: Procainamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (1 gm IV bolus, then 2 mg/min for 24 h if needed)
Study: 10443734
Drug: Neoadjuvant LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant LHRH analogue treatment (n = 50)
Study: 7878758
Drug: Once-a-day cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day cyclosporine (CsA) dosing
Study: 7878758
Drug: b.i.d. cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. cyclosporine (CsA) dosing
Study: 466592
Drug: BCG (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (120 mg) given orally at weekly intervals for 1 month, every 2 weeks up to 3 months, then every 3 months until 18 months